全文获取类型
收费全文 | 442篇 |
免费 | 54篇 |
国内免费 | 4篇 |
专业分类
儿科学 | 11篇 |
基础医学 | 77篇 |
临床医学 | 55篇 |
内科学 | 57篇 |
神经病学 | 1篇 |
特种医学 | 2篇 |
外科学 | 4篇 |
综合类 | 29篇 |
预防医学 | 218篇 |
眼科学 | 4篇 |
药学 | 42篇 |
出版年
2024年 | 1篇 |
2023年 | 3篇 |
2022年 | 22篇 |
2021年 | 13篇 |
2020年 | 16篇 |
2019年 | 19篇 |
2018年 | 11篇 |
2017年 | 9篇 |
2016年 | 12篇 |
2015年 | 20篇 |
2014年 | 21篇 |
2013年 | 46篇 |
2012年 | 28篇 |
2011年 | 23篇 |
2010年 | 30篇 |
2009年 | 22篇 |
2008年 | 44篇 |
2007年 | 37篇 |
2006年 | 25篇 |
2005年 | 11篇 |
2004年 | 12篇 |
2003年 | 8篇 |
2002年 | 6篇 |
2001年 | 3篇 |
2000年 | 11篇 |
1999年 | 1篇 |
1998年 | 7篇 |
1997年 | 4篇 |
1996年 | 9篇 |
1995年 | 3篇 |
1994年 | 5篇 |
1992年 | 2篇 |
1991年 | 4篇 |
1990年 | 1篇 |
1989年 | 1篇 |
1987年 | 1篇 |
1984年 | 1篇 |
1983年 | 1篇 |
1982年 | 2篇 |
1980年 | 1篇 |
1979年 | 1篇 |
1975年 | 1篇 |
1974年 | 1篇 |
1970年 | 1篇 |
排序方式: 共有500条查询结果,搜索用时 0 毫秒
71.
目的建立以16S rRNA基因为靶基因的聚合酶链反应(PCR)方法,用于快速检测脑膜炎奈瑟菌。方法根据GenBank公布的奈瑟菌属16S rRNA基因序列,使用DNAstar软件设计引物,应用PCR方法特异检测脑膜炎奈瑟菌,对部分菌株结合16S rRNA基因测序和APIRNH生化鉴定系统以验证该方法的准确性,同时与文献报道的检测脑膜炎奈瑟菌crgA-PCR方法进行比较。结果 16S rRNA-PCR与crgA-PCR方法检测脑膜炎奈瑟菌阳性预测值皆为100%,阴性预测值分别为100%和46.94%,假阳性率分别为0%和36.73%,假阴性率皆为0%。约登指数分别为1和0.47。对188名健康儿童咽拭子杂菌DNA应用16S rRNA-PCR和crgA-PCR方法检测脑膜炎奈瑟菌,检测阳性率分别为18.62%(35/188)和15.96%(30/188)。两者同时检测到脑膜炎奈瑟菌的标本为7.98%(15/188)。结论 16SrRNA-PCR方法特异、敏感、快速,可用于脑膜炎奈瑟菌的快速检测与鉴定。 相似文献
72.
Laura V. Cooper Anna Robson Caroline L. Trotter Abraham Aseffa Jean‐Marc Collard Doumagoum Moto Daugla Aldiouma Diallo Abraham Hodgson Jean‐Franois Jusot Babatunji Omotara Samba Sow Musa Hassan‐King Olivier Manigart Maria Nascimento Arouna Woukeu Daniel Chandramohan Ray Borrow Martin C. J. Maiden Brian Greenwood James M. Stuart 《Tropical medicine & international health : TM & IH》2019,24(4):392-400
73.
Meningoccocal disease has repeatedly caused outbreaks worldwide. There has been sudden surge of cases of meningococcemia and meningococcal meningitis in early 2005 in Delhi, India and neighboring states of Uttar Pradesh and Haryana. As of June 17, 2005, 429 probable cases of meningococcal disease have been reported in Delhi out of which 128 cases have revealed microbiological evidence of Neisseria meningitidis. It is possible that the number of cases was in excess of the numbers notified. During this episode drug susceptibility testing by MIC method (E-test) using break points recently recommended by NCCLS/CLSI, revealed that all isolates were sensitive to penicillin, ampicillin, rifampicin and ceftriaxone. As regards to ciprofloxacin, about two third of the isolates tested were found to be 'non-susceptible' (MIC =0.03microg/mL- 0.190microg/mL). All the isolates were found resistant to cotrimoxazole (MIC> 16microg/mL). Repeated outbreaks, decreased susceptibility to ciprofloxacin, which is commonly used for chemoprophylaxis of meningococcal disease, highlights the need for a constant surveillance system. Present review deals with various aspects of Neisseria meningitidis and meningococcal disease in view of recent episode. 相似文献
74.
《Expert opinion on pharmacotherapy》2013,14(15):2189-2206
Introduction: The introduction of protein conjugate vaccines for Haemophilus influenzae type b (Hib), Streptococcus pneumoniae (S. pneumoniae) and Neisseria meningitidis (N. menigitidis) has changed the epidemiology of bacterial meningitis. Bacterial meningitis continues to be an important cause of mortality and morbidity, and our incomplete knowledge of its pathogenesis and emergence of antimicrobial resistant bacteria contribute to such mortality and morbidity. An early empiric antibiotic treatment is critical for the management of patients with bacterial meningitis. Areas covered: This article gives an overview on optimal treatment strategies of bacterial meningitis, along with considerations of new insights on epidemiology, clinical and laboratory findings supportive of bacterial meningitis, chemoprophylaxis, selection of initial antimicrobial agents for suspected bacterial meningitis, antimicrobial resistance and utility of new antibiotics, status on anti-inflammatory agents and adjunctive therapy, and pathogenesis of bacterial meningitis. Expert opinion: Prompt treatment of bacterial meningitis with an appropriate antibiotic is essential. Optimal antimicrobial treatment of bacterial meningitis requires bactericidal agents able to penetrate the blood–brain barrier (BBB), with efficacy in cerebrospinal fluid (CSF). Several new antibiotics have been introduced for the treatment of meningitis caused by resistant bacteria, but their use in human studies has been limited. More complete understanding of the microbial and host interactions that are involved in the pathogenesis of bacterial meningitis and associated neurologic sequelae is likely to help in developing new strategies for the prevention and therapy of bacterial meningitis. 相似文献
75.
Orren A Owen EP Henderson HE van der Merwe L Leisegang F Stassen C Potter PC 《Clinical and experimental immunology》2012,167(3):459-471
Complete complement component 6 deficiency (C6Q0) is a co-dominant genetic disease presenting as increased susceptibility to invasive Neisseria meningitidis infections. Affected individuals have two affected alleles which can be homozygous or compound heterozygous for the particular gene defects they carry. This disorder has been diagnosed relatively frequently in Western Cape South Africans. Affected patients are prescribed penicillin prophylaxis. In 2004 we commenced a clinical follow-up study of 46 patients. Of these, 43 had family age-matched C6 sufficient controls. Participants were classified as either (i) well, or (ii) having a serious illness (SI) or died (D). An SI was a long-term illness that did not allow the performance of normal daily activities. Among 43 patients, 21 were well and 22 were SI/D, while among 43 matched controls, 35 were well and eight were SI/D. This difference is highly significant. Among all 46 C6Q0 patients, those who had had recurrent infection had significantly more SI/D than those who had suffered none or one infection. Thus, this work demonstrates the long-term serious outcome of repeated meningococcal disease (MD) episodes. We investigated the frequencies of four C6Q0 pathogenic mutations known to affect Cape patients (828delG, 1138delC, 821delA and 1879delG) in 2250 newborns. A total of 103 defective alleles (2·28%) and three affected C6Q0 individuals were detected. For all defects combined, 5·24 affected subjects (C6Q0) are expected among 10,000 individuals. What is still unknown is the number of C6Q0 individuals who suffer MD or other infectious diseases. 相似文献
76.
Knuf M Pantazi-Chatzikonstantinou A Pfletschinger U Tichmann-Schumann I Maurer H Maurer L Fischbach T Zinke H Pankow-Culot H Papaevangelou V Bianco V Van der Wielen M Miller JM 《Vaccine》2011,29(25):4264-4273
Tetravalent meningococcal serogroups ACWY conjugate vaccines will provide an advantage to those at most risk of invasive meningococcal disease; namely young children. Co-administration of ACWY-TT with DTaP-HBV-IPV/Hib was assessed in a randomized trial in 793 children aged 12-23 months. Pre-specified criteria for non-inferiority of immunogenicity following co-administration versus separate ACWY-TT and DTaP-HBV-IPV/Hib administration were reached. One month post-vaccination, ≥97.3% of ACWY-TT vaccinees had rSBA titres ≥1:8 (all serogroups). Seroprotection/seropositivity rates against DTaP-HBV-IPV/Hib antigens were ≥98.2%. The safety profile of co-administration was similar to that of DTaP-HBV-IPV/Hib alone. ACWY-TT and DTaP-HBV-IPV/Hib co-administration during the second year would facilitate introduction of ACWY-TT into routine toddler vaccination schedules. 相似文献
77.
78.
79.
《Vaccine》2022,40(12):1872-1878
BackgroundThe MenB-FHbp vaccine (Trumenba®) is licensed in various countries for the prevention of meningococcal serogroup B disease in individuals ≥ 10 years of age. The clinical development program included 11 completed trials where, in each trial, MenB-FHbp had an acceptable safety profile after a primary vaccination series was administered to individuals 10–65 years of age. However, the detection of potential rare events was limited because of individual clinical trial size. The current safety analysis evaluates pooled reactogenicity and other adverse events (AEs) reported in these trials to identify new safety signals not detectable in individual trials.MethodsEleven trials contributed safety data, of which 10 recorded local and systemic reactogenicity events; 8 of the trials were controlled, and reactogenicity data were pooled for 7 of these 8 trials. Additional AE evaluations included immediate AEs (IAEs), medically attended AEs (MAEs), serious AEs (SAEs), newly diagnosed chronic medical conditions (NDCMCs), and autoimmune or neuroinflammatory conditions.ResultsLocal and systemic reactions were more frequent in the MenB-FHbp group (n = 15,294) compared with controls (n = 5509), although most reactions were transient and mild to moderate in severity. Frequencies of IAEs, SAEs, MAEs, NDCMCs, and autoimmune or neuroinflammatory conditions were similar between the MenB-FHbp and control groups.ConclusionsMenB-FHbp demonstrated a favorable safety and tolerability profile in the clinical development program of > 15,000 vaccine recipients ≥ 10 years of age. No new safety signals were identified in the pooled analysis compared with data from the individual trials. Continued postmarketing safety surveillance is important for the identification of rare events.Clinicaltrials.gov: NCT01299480; NCT000808028; NCT00879814; NCT00780806; NCT01352845; NCT01352793; NCT01461993; NCT01323270; NCT01830855; NCT01461980; NCT01768117. 相似文献
80.
D. Vicente O. Esnal J. M. Marimon C. Gastesi E. Pérez-Trallero 《Clinical microbiology and infection》2006,12(8):812-815
Neisseria meningitidis W-135 accounted for nine (1.6%) of 562 cases of invasive meningococcal disease and 17 (3.9%) of 430 meningococcal isolates from healthy carriers. There was no mortality associated with the invasive nine isolates, which belonged to subtype P1.6 and geno-subtype P1.18-1. All invasive isolates and 15 of the 17 isolates from healthy carriers belonged to sequence type 22 by multilocus sequence typing, and showed a similarity of > 85% by pulsed-field gel electrophoresis following digestion with NheI. These results demonstrate that W-135 isolates in the Basque region of northern Spain have a high degree of similarity and are almost clonal. 相似文献